IMAX IMAX CORP Insider Trading

CEO Richard L Gelfond sold 75,919 shares at $37.05–$37.06 (Apr 16–17), now holds 765,002 shares; IMAX down 16.1% from 52-week high.

Richard L Gelfond, IMAX's Chief Executive Officer, executed 2 separate sales totaling 75,919 shares for $2,813,028.37 over April 16–17, 2026, reducing his holdings by 9.0% from 840,921 to 765,002 shares. The blended average transaction price of $37.05 lies well above the current price of $35.95 and markedly above IMAX's current position—16.1% below its 52-week high of $42.83. Notably, this filing involves a conversion of derivative securities (Table II holdings not yet visible in the database), so the 765,002 post-transaction shares in Table I do not represent Gelfond's complete economic position. The timing of these consecutive-day sales falls within a cluster of 5 prior IMAX sales executed over April 6–15, 2026 (all outcomes not yet measurable at 30 or 90 days), and his broader cross-ticker track record shows 9 prior sells with a 100.00% well-timed rate at the 90-day horizon (average 90d return after sells: -8.8%). While the CEO was able to execute at prices near the 52-week highs, the company's 39.94 P/E, 16.5% annual revenue growth, and $1.9B market cap provide no visible distress signal in fundamentals.

CEO Gelfond sells 120,132 shares at $37.14 avg in 3 trades; holds 765,002 shares post-transaction.

Richard Gelfond, IMAX's Chief Executive Officer, executed 3 separate sales totaling 120,132 shares (120.1K shares) for $4,461,339.39 ($4.5M) over three consecutive trading days (2026-04-13 to 2026-04-15) at a blended average price of $37.14. This represents a -13.6% reduction from his pre-transaction holding of 885,134 shares. The sales occurred when the stock was trading -13.5% from its 52-week high of $42.83 and -5.4% over the prior 30 days, near the lower end of recent price range. Gelfond's cross-ticker track record shows strong prior sell timing (100.00% well-timed rate across 6 prior sells), though his same-ticker history at IMAX shows mixed results with limited measurable outcomes. The company reports solid fundamentals—$106.7M quarterly revenue with +16.5% annual growth and $20.7M net income—though the P/E of 41.18 reflects elevated valuation expectations. The filing contains a derivative-conversion component, indicating this transaction involves conversion of option or warrant securities rather than a simple liquidation of open-market holdings.

CEO Richard Gelfond sold 135,046 shares of IMAX at $37.82, reducing stake by 15.0% to 765,002 shares; stock up 10.8% in 90 days

CEO Richard Gelfond sold 135,046 shares of IMAX at $37.82 on 2026-04-10 for a total of $5,106,872.53, reducing his holdings by 15.0% from 900,048 to 765,002 shares. The sale follows two other recent sells by Gelfond at this ticker (on 2026-04-06 and 2026-04-02), suggesting a pattern of share liquidation over the past week. IMAX shares have appreciated 10.8% over the past 90 days and are currently trading at $37.84, just 0.05% above the sale price, near the middle of the 52-week range of $21.44–$42.83. Gelfond's cross-ticker track record shows 5 prior sells with a 100.00% well-timed rate at the 90-day mark and an average 90d return of -8.8%, though at IMAX specifically his 2 measurable prior sales showed mixed outcomes (-6.7% and -11.0% at 90 days). The company's fundamentals remain solid with revenue of $106,654,000.00 in the latest quarter, net income of $20,657,000.00, and 16.5% annual revenue growth, though the P/E of 42.04 reflects a premium valuation relative to earnings.

CEO Gelfond sells 25,024 shares at $40.14 avg for $1.0M; stock down 8.2% from 52-week high

Richard L. Gelfond, Chief Executive Officer of IMAX, executed 2 separate sales totaling 25,024 shares for $1,004,404.82 on April 2–6, 2026, at a blended average price of $40.14. The sales reduce his holdings by 3.2% to 765,002 shares. The current stock price of $39.33 sits 8.2% below the 52-week high of $42.83, suggesting the transactions occurred near recent peak valuations. At this ticker specifically, Gelfond's 2 prior measurable sales (May 2025 and May 2023) showed 90-day outcomes of -6.7% and -11.0% respectively, establishing a 100% well-timed rate at IMAX; however, the current filing involves derivative conversion rather than a full position exit, so the signal should be framed as a partial sale of a specific batch rather than a major conviction shift. The company's fundamentals remain solid with net income of $20,657,000.00 and annual revenue growth of 16.5%, though the P/E ratio of 43.70 is elevated.

Director Douglas Kevin sold 568,000 shares (568.0K shares) for $21,481,760.00 in 6 transactions at $37.82, reducing holdings by 48.5%

Douglas Kevin, a Director, executed 6 separate sales totaling 568,000 shares for $21,481,760.00 at $37.82 on 2026-03-16, reducing his holdings from 1,170,310 shares to 602,310 shares (a 48.5% reduction in position). The sales occurred at $37.82 per share, which is below the current price of $39.05 and well below the 52-week high of $42.83. The scale of the liquidation—nearly half his holdings in a single day—combined with IMAX's strong fundamentals (Revenue $106,654,000.00, Net income $20,657,000.00, P/E 43.39, and annual revenue growth of +16.5%) and positive near-term momentum (30-day change +8.2%) represents a material insider transaction warranting attention to the director's capital allocation decisions and underlying board-level perspective on valuation.

CEO Richard L. Gelfond sold 121,220 shares of IMAX at $40.10 for $4.9M, reducing stake 13.7%; prior same-ticker sells were 100% well-timed.

CEO Richard L. Gelfond sold 121,220 shares at $40.10 on 2026-03-10, with post-transaction holdings of 765,002 shares. This sale occurs at a price $1.79 above the current $38.31 market price, and near the 52-week high of $42.83. Notably, Gelfond's prior 2 same-ticker sells at IMAX (on 2025-05-19 and 2023-05-01) were both well-timed at the 90-day mark, with negative 90-day returns of +7.7% (30d) followed by -6.7% (90d) and -17.2% (30d) followed by -11.0% (90d), establishing a consistent pattern of selling ahead of subsequent declines. The timing of this sale at elevated price levels ($40.10 vs current $38.31) combined with the insider's proven track record of well-timed exits at this ticker warrants attention to forward price action. Fundamentals remain solid with annual revenue growth of +16.5% and net income of $20.7M on $106.7M quarterly revenue, though the elevated P/E of 42.57 reflects current market expectations. A note on the derivative-conversion flag: the Form 4 Table II (derivative securities) is not yet populated, so this reported position may not capture the full scope of the CEO's economic holdings.

IMAX President Welton Mark sells 25,000 shares at $39.28; stock near 52-week high of $39.04 after +20.2% 90-day surge

Welton Mark, President of IMAX Global Theatres, sold 25,000 shares (a 16.3% reduction of prior holdings) at $39.28 on 2025-12-15, with the stock currently trading at $39.04—at its 52-week high—following a 90-day gain of +20.2%. This sale occurs as IMAX's valuation has expanded significantly: the P/E of 52.76 is notably elevated, and annual revenue has contracted by -6.0% year-over-year even as recent quarterly revenue stands at $106.7M and net income at $20.7M. Mark's cross-ticker track record across 2 prior sells shows a 100.00% well-timed rate at the 90-day mark (sales preceded declines), and his prior sale at IMAX on 2025-11-10 has posted +8.2% returns over 30 days—suggesting the stock may still be climbing post-transaction. The timing context—selling into a near-52-week-high after strong recent appreciation and amid elevated valuation multiples relative to revenue contraction—distinguishes this transaction from routine portfolio activity.

CTO Pablo Calamera sells 20,586 shares of IMAX at $34.23; holds 40,886 shares post-sale (-33.5%)

CTO and EVP Pablo Calamera sold 20,586 shares at $34.23, reducing his holdings by 33.5% to 40,886 shares and generating $704,566.14 in proceeds. This represents a significant reduction in his personal stake in IMAX at a price just below the 52-week high of $35.66, while the stock has risen 14.3% over the past 30 days and 39.2% over the past 90 days. Against this backdrop of recent strong price momentum, the timing and magnitude of the sale warrant investor attention, particularly given the company's elevated P/E of 48.19 and annual revenue decline of -6.0%, which contrast with the stock's recent positive performance.

President Mark Welton sold 49.5K IMAX shares at $35.23; holdings drop 24.4% to 153.3K post-transaction

Mark Welton, President of IMAX Global Theatres, sold 49,504 shares at $35.23 on 2025-11-10 for $1,743,926.91, reducing his shareholding by 24.4% to 153,323 shares. The sale occurs near IMAX's 52-week high of $35.66, with the stock up 14.3% over 30 days and 39.2% over 90 days—a period of significant appreciation. Notably, a prior sale by this insider on 2024-12-09 registered -7.6% return over 30 days and -1.0% over 90 days, establishing a pattern of well-timed selling at IMAX (100% of his 1 prior IMAX sale was well-timed at the 90-day mark). However, the FLAG note indicates this filing contains a derivative-conversion transaction; the insider's full position may extend beyond the Table I shares shown, with derivative holdings not yet populated in the database, so the 24.4% reduction reflects only the explicitly traded open-market batch, not his total economic exposure.

Chief Legal Officer Robert Lister sells 50,143 shares of IMAX at $34.67; retains 161,421 shares post-transaction.

Robert D. Lister, Chief Legal Officer and Senior Executive VP, sold 50.1K shares at $34.67 on 2025-11-07, reducing his holdings by 23.7% to 161.4K shares remaining. The sale occurred at a price near the 52-week high of $34.48, following strong recent momentum (stock up 7.0% in 30 days and 39.3% in 90 days). At the same-ticker level, Lister's prior sell on 2025-09-15 was followed by a 30-day decline of 3.3%, and his 2024-12-09 sale preceded a 90-day decline of 1.0%. His cross-ticker track record shows a 100% well-timed rate on sells with an average 90-day return of -1.0%, though this represents only 2 prior sales and does not necessarily predict outcomes at IMAX. The company's fundamentals show elevated valuation (P/E 46.59) against annual revenue decline of 6.0%, which provides context for a sale at peak price levels but does not confirm insider concern.